Ember Therapeutics Company Insiders
| EMBT Stock | USD 0.0001 0.00 0.00% |
Ember Therapeutics employs about 3 people. The company is managed by 3 executives with a total tenure of roughly 7 years, averaging almost 2.0 years of service per executive, having 1.0 employees per reported executive. Breaking down Ember Therapeutics' management performance can provide insight into the firm performance.
| Hyun Kim Insider VP Consultant |
| Dean Falb Insider Scientific Consultant |
Ember |
Ember Therapeutics Management Team Effectiveness
Ember Therapeutics' management efficiency ratios could be used to measure how well Ember Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Ember Therapeutics holds a total of 40 Million outstanding shares. Ember Therapeutics shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 65.0 percent of Ember Therapeutics outstanding shares that are owned by insiders denotes they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Ember Therapeutics Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Ember Therapeutics Price Series Summation is a cross summation of Ember Therapeutics price series and its benchmark/peer.
Ember Therapeutics Notable Stakeholders
An Ember Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Ember Therapeutics often face trade-offs trying to please all of them. Ember Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Ember Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
String symbol = request.getParameter("s");
About Ember Therapeutics Management Performance
The success or failure of an entity such as Ember Therapeutics often depends on how effective the management is. Ember Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Ember management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Ember management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Ember Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. Ember Therapeutics, Inc. was founded in 2010 and is headquartered in New York, New York. Ember Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange.
Please note, the imprecision that can be found in Ember Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Ember Therapeutics. Check Ember Therapeutics' Beneish M Score to see the likelihood of Ember Therapeutics' management manipulating its earnings.
Ember Therapeutics Workforce Analysis
Traditionally, organizations such as Ember Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Ember Therapeutics within its industry.Ember Therapeutics Manpower Efficiency
Return on Ember Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 7.7K | |
| Net Loss Per Executive | 7.7K | |
| Working Capital Per Employee | 19.5M | |
| Working Capital Per Executive | 19.5M |
Additional Tools for Ember Pink Sheet Analysis
When running Ember Therapeutics' price analysis, check to measure Ember Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ember Therapeutics is operating at the current time. Most of Ember Therapeutics' value examination focuses on studying past and present price action to predict the probability of Ember Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ember Therapeutics' price. Additionally, you may evaluate how the addition of Ember Therapeutics to your portfolios can decrease your overall portfolio volatility.